{"id":616466,"date":"2022-09-15T16:54:01","date_gmt":"2022-09-15T16:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=616466"},"modified":"2022-09-15T16:54:01","modified_gmt":"2022-09-15T16:54:01","slug":"advanced-ovarian-cancer-pipeline-analysis-insights-into-current-therapies-emerging-drugs-latest-fda-ema-and-pmda-approvals-clinical-trials-treatment-outlook-key-players-immunogen-celsion","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/advanced-ovarian-cancer-pipeline-analysis-insights-into-current-therapies-emerging-drugs-latest-fda-ema-and-pmda-approvals-clinical-trials-treatment-outlook-key-players-immunogen-celsion_616466.html","title":{"rendered":"Advanced Ovarian Cancer Pipeline Analysis | Insights into Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook | Key Players &#8211; ImmunoGen, Celsion"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Advanced Ovarian Cancer Pipeline Analysis | Insights into Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook | Key Players - ImmunoGen, Celsion\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Advanced Ovarian Cancer Pipeline Analysis | Insights into Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook | Key Players - ImmunoGen, Celsion\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, nearly 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Advanced Ovarian Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Advanced Ovarian Cancer Pipeline Insight, 2022<\/strong>&#8221; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Ovarian Cancer Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Advanced Ovarian Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Advanced Ovarian Cancer Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/dfc73e02881f95ee88baabdf6b022b9a.jpg\" alt=\"Advanced Ovarian Cancer Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Advanced Ovarian Cancer Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Advanced Ovarian Cancer<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the<strong> Advanced Ovarian Cancer Treatment.<\/strong><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Advanced Ovarian Cancer key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Advanced Ovarian Cancer Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the <strong>Advanced Ovarian Cancer market.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Advanced Ovarian Cancer: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Chemotherapy, surgery, and targeted cancer drugs are all treatments for Advanced Ovarian Cancer. Some women may have radiotherapy. Targeted cancer drugs can help the body control cancer cell growth. Occasionally doctors suggest radiotherapy for Advanced Ovarian Cancer. Radiotherapy can shrink tumors and reduce symptoms.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Developments in the&nbsp;Advanced Ovarian Cancer Therapeutics Market<\/strong><\/p>\n<p style=\"text-align: justify;\"><em>&bull; On&nbsp;September 15, 2022,&nbsp;<strong>Celsion Corporation (NASDAQ: CLSN)<\/strong>&nbsp;announced that its <strong>Phase I\/II OVATION 2 Study<\/strong> with <strong>GEN-1<\/strong> in&nbsp;Advanced Ovarian Cancer had completed enrollment. GEN-1 is Celsion&rsquo;s IL-12 gene-mediated immunotherapy.<\/em><\/p>\n<p style=\"text-align: justify;\"><em>&bull;&nbsp;On September 11, 2022, <strong>Clovis Oncology, Inc. (NASDAQ: CLVS)<\/strong>, announced results from a subgroup analysis of data from the monotherapy comparison of the randomized, <strong>Phase 3 ATHENA (GOG-3020\/ENGOT-ov45) trial (ATHENA-MONO)<\/strong> at the <strong>European Society of Medical Oncology (ESMO) Congress 2022<\/strong> in Paris. The data demonstrated that Rubraca as a first-line maintenance treatment enhanced progression-free survival (PFS) across disease risk subgroups.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Report covers around 50+ products under different phases of clinical development like<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Late-stage products (Phase III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Mid-stage products (Phase II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Early-stage product (Phase I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Pre-clinical and Discovery stage candidates<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Discontinued &amp; Inactive candidates<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Route of Administration<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/advanced-ovarian-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Advanced Ovarian Cancer Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">There are approx. <strong>50+ key companies<\/strong> which are developing therapies for Advanced Ovarian Cancer. <strong>ImmunoGen<\/strong> has its Advanced Ovarian Cancer drug candidates in the most advanced stage (<strong>phase III<\/strong>) of clinical development.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key companies in the Advanced Ovarian Cancer Therapeutic Market include:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>ImmunoGen, Celsion Corporation,&nbsp; Clovis Oncology,&nbsp;OncoQuest, Lee&#8217;s Pharmaceutical, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, Puma Biotechnology, Inc., MaxCyte, Inc., Bayer, Xennials Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc, and others.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Advanced Ovarian Cancer Emerging Drugs<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Mirvetuximab soravtansine (IMGN853 (ImmunoGen)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Oregovomab (OncoQuest)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp;&nbsp;<br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/advanced-ovarian-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Advanced Ovarian Cancer Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Advanced Ovarian Cancer &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Advanced Ovarian Cancer Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Advanced Ovarian Cancer Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Advanced Ovarian Cancer Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Advanced Ovarian Cancer Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Advanced Ovarian Cancer Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Key Companies in the Advanced Ovarian Cancer Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Advanced Ovarian Cancer Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Advanced Ovarian Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Advanced Ovarian Cancer Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Advanced Ovarian Cancer Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/advanced-ovarian-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/platinum-resistant-relapsed-ovarian-cancer-market\">Platinum-Resistant Relapsed Ovarian Cancer Market<br \/><\/a><\/strong>&ldquo;Platinum-Resistant Relapsed Ovarian Cancer Market&rdquo; research report provides a detailed overview of the historical and forecasted epidemiology as well as the Platinum-Resistant Relapsed Ovarian Cancer Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=advanced-ovarian-cancer-pipeline-analysis-insights-into-current-therapies-emerging-drugs-latest-fda-ema-and-pmda-approvals-clinical-trials-treatment-outlook-key-players-immunogen-celsion\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=advanced-ovarian-cancer-pipeline-analysis-insights-into-current-therapies-emerging-drugs-latest-fda-ema-and-pmda-approvals-clinical-trials-treatment-outlook-key-players-immunogen-celsion\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, nearly 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Advanced Ovarian Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/advanced-ovarian-cancer-pipeline-analysis-insights-into-current-therapies-emerging-drugs-latest-fda-ema-and-pmda-approvals-clinical-trials-treatment-outlook-key-players-immunogen-celsion_616466.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,425,426,417,404],"tags":[],"class_list":["post-616466","post","type-post","status-publish","format-standard","hentry","category-Business","category-Finance","category-Financial-Market","category-Marketing-Sales","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616466","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=616466"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616466\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=616466"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=616466"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=616466"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}